Drug intelligence / Profile preview

hazel pollen extract

Development stage
Unknown
Modality
Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration
Sublingual, Subcutaneous, Intradermal
01

Overview

Hazel pollen extract is an allergenic extract derived from the pollen of the hazel tree, *Corylus avellana*. It is used as an active ingredient in allergen immunotherapy to treat individuals with allergic rhinoconjunctivitis and/or allergic asthma triggered by hazel pollen. [4] The therapeutic principle involves administering controlled, gradually increasing doses of the pollen allergens to desensitize the patient's immune system. This process aims to induce immune tolerance, thereby reducing or eliminating the allergic symptoms that occur upon natural exposure to the pollen. Due to significant cross-reactivity between allergens of trees in the birch homologous group, hazel pollen extract is often included in mixed-tree pollen preparations alongside extracts from birch (*Betula*) and alder (*Alnus*) for sublingual (SLIT) or subcutaneous (SCIT) immunotherapy. [4, 11] These products are designed to provide broader protection throughout the tree pollen season. [11] While some products, like ALK's ITULATEK, are based on birch pollen extract, they are also indicated for patients sensitized to hazel due to this cross-reactivity. [12, 14]

Other names
Corylus avellana pollen extract
02

Targets

IgE (Immunoglobulin E)T-cell receptor recognizing hazel allergen-derived peptides presented by MHC class II

Beyond the preview

Go deeper on hazel pollen extract.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on hazel pollen extract.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call